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F ollowing a 3 February vote in the UK House of Commons, the world may once again look to Britain to lead in fertility treatments, 37 years after in vitro fertilization (IVF) was pioneered in the country.
The vote lifts a ban on gene-altering fertilization techniques known as mitochondrial replacement, or three-person IVF, in which mitochondria -the cell's energy-processing structures -from a donor's egg cell contribute to a couple's embryo. The procedures are intended to prevent the transmission of diseases caused by mutations in mitochondrial DNA. The vote, won by 382 in favour versus 128 against, will still need to be confirmed by the House of Lords, which is widely expected to pass the law. Once approved, the Human Fertilisation and Embryology Authority (HFEA), Britain's fertility regulator, will be allowed to license clinics to carry out the procedures from October, although it could be some time before the first human trials begin.
Many reproductive biologists see this as a step that will affect the field on a global scale. "We've been hoping that the UK will take the lead, " says Shoukhrat Mitalipov, a stem-cell scientist at Oregon Health & Science University in Portland. His team hopes to apply to the US Food and Drug Administration (FDA) for permission to conduct clinical trials of mitochondrial replacement. Although its regulatory debate is a bit behind the United Kingdom's, "the US is going down the same path", Mitalipov says.
An estimated 1 in 5,000 children are born with diseases caused by mitochondrial mutations, which typically affect energy-hungry tissues such as the brain, heart and muscles. All mitochondrial DNA is inherited from the mother, and some women carry harmful mitochondrial mutations without having symptoms themselves. Like ageing Crown princes, junior biomedical researchers in the United States face long years as leaders-in-waiting. Now, in a 3 February posting, the NIH has asked researchers whether the agency would be wise to give 'emeritus grants' to senior scientists to induce them to wrap up their research. The funding would "help to ensure the orderly transition of an experienced researcher's work when they wish to go on to something else, and also to recognize their legacy", says Sally Rockey, the NIH's deputy director for extramural research. If entrenched grant recipients leave the lab, the NIH hopes, more money will be available for early-career scientists.
Those who support the idea say that it could ease the pressure on senior researchers to continue working in order to bolster their retirement accounts, which in the United States largely depend on employee contributions. The evidence for this is anecdotal, however, and proponents of emeritus grants admit that few senior researchers complain that they lack money to close their labs.
But judging from more than 100 comments left on Rockey's widely read blog, many researchers are highly sceptical of the plan, and are incensed by what they perceive as a retirement bonus for the already better-resourced. "The idea of allocating precious limited federal research dollars to a special 'emeritus' award appears, at best, tone deaf, and at worst, suggests underlying biases within the NIH that favour established researchers, " says neuroscientist Benjamin Saunders, a postdoctoral researcher at Johns Hopkins University in Baltimore, Maryland.
Economic research suggests that paying older scientists to abandon their labs is unlikely to be the most effective way for the NIH to achieve its ultimate goal. Policies for adjusting markets work better when they are direct, says labour economist Richard Freeman of the National Bureau of Economic Research in Cambridge, Massachusetts. "If your goal is to have more young researchers have independent awards and positions, it would be more efficient just to give them that, " he says. "Any time you try indirect methods, there is much more uncertainty as to what will happen. "
But the NIH has had mixed success with policies designed to give more money to new investigators. Since 2007, the percentage of grants won by new applicants has approached the share reaped by experienced scientists (see ' Age gap'), but critics say that funded proposals from younger researchers are of lower quality than those from older scientists. And despite the NIH's efforts, the average age at which a researcher wins his or her first award has not declined.
This may be partly because of broader demographic changes in the biomedical workforce. About 1 in 3 working scientists was over 50 in 2010, compared with 1 in 5 in 1993. This helps to explain why the average age of NIH principal investigators has risen. The age of first innovation itself might be increasing, too, according to analyses of patent filings and the age at which Nobel laureates win their prizes. Benjamin Jones, an economist at Northwestern University in Evanston, Illinois, has found that over the past century there has been a shift towards productive science at older ages, perhaps because innovation now requires more knowledge 2 . An even bigger challenge is an imbalance between the healthy supply of young scientists and the number of senior-level jobs, says Michael Teitelbaum, a demographer at Harvard Law School in Cambridge, Massachusetts. The problem has been exacerbated by erratic NIH funding. From 1998 to 2003, the agency's budget doubled, to US$27.2 billion. Flush with grant money, academic research centres expanded, making jobs for biomedical-
POLICY
NIH ponders 'emeritus grants'
A proposal to pay senior biomedical researchers to wind down their labs draws scepticism.
fatal conditions such as muscular dystrophy or heart disorders.
Before giving a green light to clinics wishing to offer the treatment, the HFEA will probably want further evidence that the procedure is safe, and will vet applications on a case-by-case basis.
The United Kingdom was one of the few countries that explicitly banned mitochondrial replacement by law. In many countries, including China and Japan, the techniques are prevented by regulations that should be simpler to overturn, without legislative intervention, says Tetsuya Ishii, a bioethicist at Hokkaido University in Japan.
The same applies to the United States.
Since 2001, the FDA has enforced a moratorium on mitochondrial replacement, after a New Jersey fertility clinic conducted a related procedure to improve conception rates. Mitalipov's push to launch a clinical trial of mitochondrial replacement set off a series of scientific, ethical and policy reviews that are still under way. In February 2014, an FDA advisory panel held a two-day meeting to consider the science of mitochondrial replacement. The panel identified areas in which it wanted to see more data, such as the long-term health of monkeys conceived through the procedures, before it could move to allow mitochondrial replacement.
It will probably take two to five years to fill in these gaps, says Evan Snyder, a stemcell biologist at Sanford-Burnham Medical Research Institute in La Jolla, California, who is chair of the FDA panel.
Australia is also pondering three-person IVF. Although the country's lawmakers opted against relaxing the rules after a 2011 review of human-cloning legislation, the UK vote will "provide enormous ammunition" for those seeking changes, says David Thorburn, a geneticist at the University of Melbourne, Australia. Still, he adds, "my gut feeling is that it's unlikely to succeed until this has been done in practice in the UK". ■
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